Agios Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian Goff
- Full Time Employees
- 540
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 88 Sidney Street Cambridge MA United States of America 02139
- IPO Date
- Jul 24, 2013
- CIK
- 0001439222
- Website
- agios.com
- Similar Companies
- Business
- Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing transformative therapies primarily in the field of cellular metabolism, with a near-term emphasis on rare diseases such as hemolytic and acquired anemias. Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios develops precision medicines including its flagship product, Pyrukynd (mitapivat), an oral activator of pyruvate kinase enzymes targeting hemolytic anemias such as pyruvate kinase deficiency and sickle cell disease. Its product portfolio also involves investigational candidates like tebapivat, a next-generation PK activator, and AG-236, aimed at addressing broader metabolic and hematologic disorders. The company’s offerings encompass small-molecule drugs and supportive patient services programs like myAgios to facilitate access and treatment adherence. Recent major developments include the positive results from the ACTIVATE-Kids Phase 3 study demonstrating the efficacy of mitapivat in pediatric patients with pyruvate kinase deficiency, establishing a pathway for pediatric label expansion. Agios is preparing for the U.S. commercial launch of Pyrukynd in multiple hemolytic anemia indications including sickle cell disease and thalassemia in 2026, supported by increased commercial infrastructure and headcount expansion. The company is advancing pipeline diversification with an IND filing planned for mid-2025 for AG-236 and Phase 2 trials for tebapivat in sickle cell disease, reinforcing its strategic objective to treat a broad spectrum of rare blood disorders through oral, disease-modifying therapies. Agios also concentrates on expanding its research into cancer metabolism as a complementary segment. Agios Pharmaceuticals operates primarily in the United States with its products addressing unmet needs in the rare genetic disease market and hematology segments. It leverages advanced technologies in metabolic pathway targeting, small molecule drug discovery, and clinical development. The company’s strategic alliances, regulatory progress, and patient-centric commercialization programs position it as a leader in the transformative rare disease therapy space. Its founding scientific focus on cellular metabolism continues to drive innovation across both rare hematologic diseases and oncology therapeutic areas. This comprehensive portfolio and recent clinical and commercial advances underline Agios’s commitment to providing long-term, disease-modifying treatments for patients with rare metabolic diseases and blood disorders.
Company News
Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Hold” by Brokerages
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
Agios Pharmaceuticals Q2 Earnings Call Highlights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
Agios Pharma to discontinue sickle cell disease treatment development